Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0005940 (bone disease)
 7,459 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Since the introduction of bone scans in 1951, there have been many studies comparing biologic and physical characteristics of new bone-imaging agents and the results of scintigraphy and radiology in large numbers of patients. Relatively speaking, there have been fewer studies detailing the health benefits and financial cost associated with the use of skeletal scintigraphy. This review concerns these aspects in patients with malignancies of various sites and stages. About 2% of patients with stage I or II breast cancer have bone metastases at the time they first present, whereas nearly 28% of patients with stage III disease have bone metastases. A large percentage of patients with initially negative scans develop bone metastases during the first 3--4 yr; many of them develop them within the first 12--18 mo after initial diagnosis. For patients with lung cancer, the use of bone scans in staging their disease is somewhat controversial. Several studies indicate that the yield of positive bone scans may range from as low as 2% to as high as 35%. Data on the use of bone scans in staging prostatic cancer initially are similar to those in patients with breast cancer, that is, yields of 7% in patients with stage I or II disease and a yield of about 20% with stage III disease. Children with osteosarcoma or Ewing's sarcoma rarely have bone disease distant from the site of their primary bone lesion at presentation. However, a large percentage of them (30%--40% or so) develop bone metastases during the follow-up period. As in the case with patients with breast cancer, about half of these bone metastases are evident by 12--18 mo.
 ...
PMID:Rationale for the use of bone scans in selected metastatic and primary bone tumors. 11 84

Bone scintigraphy with 99mTc-polyphosphate or 99mTc-pyrophosphate was carried out in 54 children suspected of bone disease. Signs of skeletal metastases were recognized in 13 children by scintigraphy whereas X-ray examination showed lesions in only 10 of these. In 5 children with primary osteosarcoma, three cases of fibrous dysplasia, and 4 cases of osteomyelitis, the lesions were clearly demonstrated by scintigraphy. Abnormal accumulation of radioactivity in soft tissue lesions was observed in primary adrenal neuroblastoma, Hodgkin's granuloma, and metastatic Burkitt's lymphoma. Several cases are reported, and the value of bone scintigraphy in children is discussed.
 ...
PMID:Bone scintigraphy in children. 18 23

A female pet wooly monkey with metabolic bone disease initially presented with a proliferating bony mass in the left humerus which had many features of osteosarcoma. At necropsy, parathyroid hyperplasia, osteoclastic resorption, proliferative osteoid deposition in the calvarium and cortex of long bones, and fibrous proliferation of the marrow indicated the presence of generalized osteodystrophia fibrosa. The dietary history of deficient vitamin D3 and protein and minimal exposure to sunlight supported this diagnosis, as did depressed levels of serum calcium and elevated levels of serum parathyroid hormone, alkaline phosphatase, and acid phosphatase.
 ...
PMID:Metabolic bone disease resembling osteosarcoma in a wooly monkey (Lagothrix lagotricha). 21 39

A method based on the intravenous 133Xe injection technique has been used for measurement of bone blood flow in man. The measurements were made from the greater trochanteric region of the femur of eight healthy subjects and three patients with bone marrow or a bone disease in which bone blood flow is known to be increased. The half-times of the fast and the slow compartments of the externally recorded two-exponential bone washout curves were 4.05 +/- 0.88 min and 45.4 +/- 7.4 min (mean +/- 1 sd) in the healthy subjects, 1.46 min and 20.1 min in the patient with chronic myeloid leukemia, 2.50 min and 22.9 min in metastic bone disease and 1.93 min and 18.1 min in the patient with osteosarcoma, respectively. The corresponding flow values were 11.5 +/- 1.4 ml/100 g/min (mean +/- 1 sd) in healthy subjects and 59.8, 28.3 and 34.0 ml/100 g/min in patients with bone disorders. The precision of the method estimated from the duplicate measurements in eight healthy persons is; for the fast compartment, 6.8%; and for the slow one, 3.2%. Because of the rapid washout of xenon and the very low radiation dose the measurements are easily repeatable.
 ...
PMID:Measurement of bone blood flow with a 133 Xe washout method. A preliminary report. 29 60

The teleangiectatic osteosarcoma is an extremely malignant tumor of the bone with rapid progression and short time of survival. In a 57 y.o. male such a tumor in the right proximal femur was diagnosed. Previously for 13 years a cystic bony lesion was known and followed in consequent intervals radiologically and clinically. There was no change in appearance till all at once malignant change developed. Systemic bone disease as ethiopathogenetic factor (e.g. ostitis deformans Paget) could be excluded. This case demonstrates an uncommon development of a teleangiectatic osteosarcoma out of a radiologically benign bony cyst, consequently followed for 13 years.
 ...
PMID:[Highly malignant telangiectatic osteosarcoma. Long-term follow-up]. 183 3

Bone-seeking radionuclides have been used to treat bone pain due to metastatic bone disease for over 40 years. More than 10 clinical studies using radiostrontium (Sr-89) have shown benefit in about 70-80% of patients having refractory bone pain from prostate, breast and other metastatic bone cancers, with minimal hematological toxicity. Other radionuclides, such as, radiophosphate (P-32), Yttrium-90, lodine-131, Rhenium-186, have also been used. Tumor necrosis has been found within the range of beta irradiation from the surrounding shell of bone incorporating the radionuclide. New strategies using radionuclides may be able to provide more effective methods of treatment, perhaps, beyond palliation. For example, the effect of low dose continuous radiation can be potentiated by hypoxic cell sensitizers. In addition, the kinetics of radionuclide uptake and retention can be modulated to increase the dose of radiation delivered to osteoblastic metastatic lesions, such as osteosarcoma.
 ...
PMID:A new look at radionuclides therapy in metastatic disease of bone (review and prospects). 246 20

Novel proteins synthesize predominantly in bone have been identified by antibody screening of bone cell cDNA expression libraries. Two unique cDNAs were identified whose structures do not match any known nucleic acid or protein sequence in the NIH computer bank. The first cDNA clone, BP-I, encoded a mRNA of 2300 bases in size which was expressed at high levels in 17/2.8 rat osteosarcoma cells, rat calvarial bone cells and placenta. A second clone, BP-II, encoded a mRNA of 1500 bases which was expressed at high levels in 17/2.8 osteosarcoma cells and in salivary gland. Expression of both mRNAs in osteosarcoma cells was modulated by the calciotropic hormone, vitamin D. Southern blot analyses indicated that the two cDNAs represented distinct, single copy genes in the rat genome. These novel gene products may serve as potential new markers to study bone turnover in metabolic bone disease.
 ...
PMID:Identification of novel proteins synthesized in bone cells by antibody screening of a cDNA expression library. 316 63

Twelve patients with osteosarcoma were evaluated by plain radiographs, radionuclide bone scans and computed tomography (CT). Plain films were the primary radiologic tool for the investigation and follow-up of the skeletal lesion and were particularly helpful for the demonstration of periosteal calcification and bone permeation. The main value of the radiophosphate scan was to detect metastatic or multifocal bone disease. CT was able to show new bone formation in the soft-tissue mass not seen on plain films, to determine proximal intramedullary extension and to assess the response of the bone lesion to preamputation chemotherapy. The lungs were followed at regular intervals with plain chest radiographs and CT scans.
 ...
PMID:Radiologic evaluation of osteosarcoma. 695 77

Bone cells respond to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) for mineral mobilization and contain receptors for 1,25(OH)2D3. We report here the expression of 25-hydroxyvitamin D3 (25 (OH)D3) metabolizing enzymes in primary cultures of human bone cells, as well as n a human osteosarcoma cell line. Human bone cells were obtained by enzyme digestion of the extracellular matrix of bone from iliac crest biopsies from 3 male patients without primary bone disease. These cells were plated (5 X 10(4)/min) in medium with 10% fetal calf serum and proliferated to confluence in 10-14 days. At confluence, the medium was replaced with serum-free medium. The cells were preincubated in this serum-free medium for 24 h prior to incubating them 2-4 h with [3H]25(OH)D3 (10-20 nM). The vitamin D metabolites synthesized during this incubation were extracted from the medium and cells with dichloromethane, then separated by chromatography on Sephadex LH-20, followed by high performance liquid chromatography. The cells synthesized 1,25(OH)2D3 and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) with the specific activities of the 1- and 24-hydroxylases similar in magnitude to those in kidney cells in vitro. The enzymes could be regulated by external perturbations, in that the activity of the 1-hydroxylase was inhibited by preincubation of the cells for 8 h with 1,25(OH)2D3 (10 nM), whereas the 24-hydroxylase was enhanced. Incubation of the cells in a low calcium medium (0.6 mM) depressed the 24-hydroxylase activity. We conclude: 1) normal human bone cells can produce 1,25(OH)2D3 and 24,25(OH)2D3 in vitro in amounts similar to kidney cells, suggesting a physiological significance and 2) this synthesis could account for the increase in osteoclast number in anephric patients with renal osteodystrophy.
 ...
PMID:Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. 697 69

With a brother and sister, osteosarcoma developed at the age of 11 and 14 respectively. With both there was no previous retinoblastoma or other bone disease with a proclivity to develop osteosarcoma. We discuss possible explanations for familial aggregation of osteosarcoma, citing external or genetic factors. We suggest that it is the retinoblastoma gene RB and the tumor suppressor gene p53 which play an important part in the development of osteosarcoma.
 ...
PMID:[Osteosarcoma in 2 siblings. A case report]. 750 Jun 7


1 2 3 4 5 Next >>